Table 1 Baseline characteristics and treatment effect of all included patients
Age, years; median (range) | 66 (24–89) |
Observation period, days; median (range) | 100 (7–1514) |
Sex | |
Male | 78 (60%) |
Female | 53 (40%) |
Primary site | |
Lungs | 35 (27%) |
Genitourinary tract | 34 (26%) |
Gastrointestinal tract | 34 (26%) |
Breasts | 6 (5%) |
Head and neck | 5 (4%) |
Thyroid | 4 (3%) |
Gynecology | 4 (3%) |
Unknown | 9 (7%) |
Histology | |
Squamous cell carcinoma | 9 (7%) |
Adenocarcinoma | 66 (50%) |
Small cell carcinoma | 4 (3%) |
Clear cell carcinoma | 22 (17%) |
Others | 27 (21%) |
Unknown | 3 (2%) |
Imaging modality | |
CT (including simulation CT) | 131 (100%) |
MRI | 54 (41%) |
Bone scintigraphy | 56 (43%) |
18FDG-PET | 14 (11%) |
Metastatic site | |
Vertebral | 86 (66%) |
Non-vertebral | 45 (34%) |
Bone metastases type | |
Osteolytic | 88 (67%) |
Osteoblastic | 34 (26%) |
Mixed | 9 (7%) |
Pathological fracture | |
Present | 24 (18%) |
Absent | 107 (82%) |
Treatment effect | |
Response | 105 (80%) |
Non-response | 26 (20%) |